The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum and ...

Inmagene Biopharmaceuticals merges with Ikena Oncology to form InmageneBio, focusing on IMG-007, an OX40-targeting antibody ...

AusperBio raises $73 million in series B funding to advance Phase II trials of AHB-137, its antisense oligonucleotide therapy ...

Japanese drugmaker Kaken Pharmaceutical has entered into a license agreement with US healthcare giant Johnson & Johnson for ...

Mumbai, India-based Mankind Pharma has entered into a partnership with China’s Innovent Biologics for exclusively licensing ...

Akums secures a strategic deal to manufacture and supply oral liquid formulations for a global pharma company in Europe. The ...

The US Food and Drug Administration (FDA) has issued the Federal Register notice, Modifications to Labeling of ...

The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved the use of Hyqvia (immune globulin infusion 10% [human ...

Riemser is a pan-European specialty pharma company that has strengths in the marketing and distribution of pharmaceuticals in niche areas of oncology, neurology, infectious diseases and other fields.

A fully integrated global biopharma company headquartered in Lugano, Switzerland. It is focused on improving the lives of cancer patients all over the world with a leading position in cancer ...

39-43 Putney High Street, Putney London, SW15 1SP United Kingdom ...

AstraZeneca and Daiichi Sankyo withdraw EU application for datopotamab deruxtecan in NSCLC after Phase III trial shows no ...